About Us

MISSION STATEMENT: The HIV+Hepatitis Policy Institute promotes quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions.

Monitors policies that impact the prevention and treatment of HIV, viral hepatitis, and other health conditions in the United States.

Communicates with members of the HIV, hepatitis, and other patient group communities on key policy issues that impact their access to healthcare.

Educates policymakers and members of the media about efforts to end both HIV and hepatitis in the United States and to improve access to quality and affordable healthcare for people with or at risk of serious or chronic health conditions.

Our Team

CARL SCHMID

Executive Director, HIV+Hepatitis Policy Institute, Washington, D.C.

cschmid@hivhep.org

Carl Schmid has been a national policy and advocacy leader in the HIV community for over 20 years.  He spent 16 years with The AIDS Institute, serving as its Deputy Executive Director. In December 2019, he formed the HIV+Hepatitis Policy Institute, which promotes quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions.

Mr. Schmid leads advocacy efforts to ensure domestic HIV and hepatitis programs are based on sound public policy and fully funded. He has expertise in healthcare financing systems, including Medicaid and Medicare, and leads efforts to ensure that the Affordable Care Act meets the needs of beneficiaries, including prescription medications.

From December 2018 to August 2021 he served as Co-Chair of the Presidential Advisory Council on HIV/AIDS (PACHA). He currently serves as a member of PACHA and as a consumer representative to the National Association of Insurance Commissioners. 

He is a cancer survivor and living with chronic hepatitis B.

Mr. Schmid earned a B.A. in Public Affairs and an M.B.A. in International Affairs from the George Washington University in Washington, D.C.

Scott Palmer

Executive Assistant

spalmer@hivhep.org

Ann Lefert

The Lefert Group

Policy Consultant

ann@thelefertgroup.com

Jennifer Burke

Communications Consultant

jburke@hivhep.org

Board Members

CARL SCHMID

President

Executive Director

HIV+Hep Policy Institute

Washington, DC

REKHA RAMESH

Treasurer 

Executive Director, Policy

Gilead Sciences, Inc.

Foster City, CA

JUSTIN C. SMITH MS, MPH

Secretary

Director, Campaign to End AIDS

Positive Impact Health Centers

Atlanta, GA

JAMES CAREY

Head of U.S. Government Affairs and Policy

Organon and Co.

Washington, DC

MARC MEACHEM

Director of External Affairs

ViiV Healthcare

Washington, DC

RAFAELÉ NARVÁEZ

Co-Founder

Latinos Salud

Oakland Park, FL

ANDREW SPERLING

Director of Federal Legislative Advocacy

National Alliance on Mental Illness

Arlington, VA

PAM TRAXEL

Senior Vice President

American Cancer Society

Cancer Action Network

Washington, DC

STEVEN R. YOUNG

Former Director

HIV/AIDS Bureau, HRSA, HHS

Yardley, PA

Funders for HIV+Hepatitis Policy Institute

HIV+Hep appreciates the support of numerous funders, and recognizes those below that are our corporate members and sponsors:

Get Involved

Facebook posts by @HIV+Hep

Tweets by @HIV+Hep

5 hours ago
Join @HIVHep’s Carl Schmid on 9/21, 5:30pm ET, @ the virtual @2021SYNC, where he will address the #ACA requirement for insurers to offer #PrEP w/o patient cost-sharing & ways to increase #PrEP uptake. To register & see the conference agenda, please visit https://t.co/x9p29DJ27F. https://t.co/3SvOLB1iV4 HIVHep photo
6 hours ago
Excision's CRISPR gene editing therapy for HIV is heading into human testing after FDA clearance https://t.co/5ccg86Jw9c
7 hours ago
@HIVHep encourages orgs to join a letter in support of an expedited USPSTF review of anticipated long-acting #PrEP that is superior to current #Rx available: https://t.co/5y7sBnMg6k. Please sign on before noon ET, 9/30: https://t.co/oEI9qQkjuc. https://t.co/NnP46UE2zi HIVHep photo
23 hours ago
@HIVHep is looking for organizations to sign on to a letter urging the USPSTF to review soon to be FDA approved long-acting #PrEP: https://t.co/5y7sBnMg6k. To sign on before noon ET, 9/30, go to: https://t.co/oEI9qQkjuc.

Pin It on Pinterest

Share This